Hiroshi Fujiwara, Masashi Kubota, Yu Hidaka, Kaoru Ito, Takashi Kawahara, Ryoma Kurahashi, Yuto Hattori, Yusuke Shiraishi, Yusuke Hama, Noriyuki Makita, Yu Tashiro, Shotaro Hatano, Ryosuke Ikeuchi, Masakazu Nakashima, Noriaki Utsunomiya, Yasushi Takashima, Shinya Somiya, Kanji Nagahama, Takeru Fujimoto, Kosuke Shimizu, Kazuto Imai, Takehiro Takahashi, Takayuki Sumiyoshi, Takayuki Goto, Satoshi Morita, Takashi Kobayashi, Shusuke Akamatsu
BACKGROUND: The treatment and prognosis of de novo metastatic hormone-sensitive prostate cancer (mHSPC) vary. We established and validated a novel prognostic model for predicting cancer-specific survival (CSS) in patients with mHSPC using retrospective data from a contemporary cohort. METHODS: 1092 Japanese patients diagnosed with de novo mHSPC between 2014 and 2020 were registered. The patients treated with androgen deprivation therapy and first-generation anti-androgens (ADT/CAB) were assigned to the Discovery (N = 467) or Validation (N = 328) cohorts...
July 19, 2024: International Journal of Clinical Oncology
Brian Na, Shilp R Shah, Harish N Vasudevan
No abstract text is available yet for this article.
July 19, 2024: Current Oncology Reports
Ege A Sarıkaya, Volkan Şen, Kutsal Yörükoğlu, Ozan Bozkurt
INTRODUCTION: High cord radical orchidectomy (HRCO) is accepted as the standard surgical approach in testicular cancer, however low cord orchidectomy (LCRO) can reduce the morbidity of operation without worsening the oncological outcomes. METHODS: We retrospectively re-examined the specimens of men to determine the level of spermatic cord invasion (SCI). Men who had proximal SCI with negative surgical margins after HRCO were assumed to have de-novo residual tumour if LCRO was performed...
July 19, 2024: World Journal of Urology
Sophia Drabke, Justus Kaufmann, Heinz Schmidberger
No abstract text is available yet for this article.
July 19, 2024: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
Nancy E Avis, Beverly J Levine, Heidi D Klepin, Shannon L Mihalko, Peter H Brubaker, Tonya Moore, Amy C Ladd, Susan F Dent, Mary Helen Hackney, Bonnie Ky, William O Ntim, Lynne I Wagner, Kathryn E Weaver, W Gregory Hundley
PURPOSE: To examine the differential effect of non- and anthracycline-based chemotherapy on fatigue over 12 months post-diagnosis among breast cancer survivors. METHODS: This study is based on a prospective Wake Forest NCI Community Oncology Research Program (NCORP) multicenter cohort study (WF-97415) of women with stage I to III breast cancer and non-cancer controls. Analyses compared those: 1) receiving, or 2) not receiving anthracycline chemotherapy, 3) receiving aromatase inhibitors (AIs) without chemotherapy, with 4) a comparator group without a history of cancer...
July 19, 2024: Supportive Care in Cancer
Hammoda Abu-Odah, Doris Leung, Engle Angela Chan, Jonathan Bayuo, Jing Jing Su, Ka-Yan Ho, Katherine-Ka-Wai Lam, John Wai-Man Yuen, Ivy Yan Zhao, Matthew J Allsop, Fadi M Al Zoubi, Mohammed N Al Khaldi, Eric L Krakauer, Alex Molassiotis
BACKGROUND: Caring for patients with advanced cancer is complex and challenging, requiring varied expertise, including symptom management, communication skills, care coordination and emotional resilience. Within existing literature, the lived experiences of oncology nurses are poorly articulated in countries with a lower income where formal palliative care (PC) is absent. AIM: To explore the lived experiences of Gazan oncology nurses who provide care to patients with advanced cancer in healthcare systems, without formal palliative care infrastructure...
July 2, 2024: International Journal of Palliative Nursing
Xin Wei, Xiaosong Li, Ziyan Guo
Dose selection and optimization in early phase of oncology drug development serves as the foundation for the success of late phases drug development. Bivariate Bayesian logistic regression model (BLRM) is a widely utilized model-based algorithm that has been shown to improve the accuracy for identifying recommended phase 2 dose (RP2D) based on dose-limiting-toxicity (DLT) over traditional method such as 3 + 3. However, it remains a challenge to optimize dose selection that strikes a proper balance between safety and efficacy in escalation and expansion phase of phase I trials...
July 19, 2024: Journal of Biopharmaceutical Statistics
Michael Colin Mowrer, Lisa Lima, Rohit Nair, Xilong Li, Hitesh Sandhu, Brian Bridges, Ryan P Barbaro, Saleh Bhar, Raymond Nkwantabisa, Saad Ghafoor, Agnes Reschke, Taylor Olson, Matthew P Malone, Neel Shah, Matt S Zinter, Jon Gehlbach, Laura Hollinger, Briana L Scott, Reut Kassif Lerner, Thomas V Brogan, Lakshmi Raman, Renee M Potera
OBJECTIVE: To describe characteristics associated with survival for pediatric patients with an oncologic diagnosis or hematopoietic cell transplant (HCT) supported with extracorporeal membrane oxygenation (ECMO). DESIGN: Multicenter, retrospective study. SETTING: Sixteen PICUs in the United States and Israel. PATIENTS: We included patients aged younger than 19 years with an oncologic diagnosis or HCT who required ECMO support between 2009 and 2021...
July 19, 2024: Pediatric Critical Care Medicine
Faith C Robertson, Brian V Nahed, Garni Barkhoudarian, Anand Veeravagu, David Berg, Steven Kalkanis, Jeffrey J Olson, Isabelle M Germano
Clinical guidelines direct healthcare professionals toward evidence-based practices. Evaluating guideline impact can elucidate information penetration, relevance, effectiveness, and alignment with evolving medical knowledge and technological advancements. As the American Association of Neurological Surgeons/Congress of Neurological Surgeons Section on Tumors marks its 40th anniversary in 2024, this article reflects on the tumor guidelines established by the Section over the past decade and explores their impact on other publications, patents, and information dissemination...
July 19, 2024: Neurosurgery
Sam Lyvannak, Bun Sereyleak, Mariko Kakazu, Hor Bisiphan, Jason Jarzembowski, Bruce Camitta
No abstract text is available yet for this article.
July 19, 2024: Journal of Pediatric Hematology/oncology
Sam Lyvannak, Bun Sereyleak, Frank G Keller, Jason Jarzembowski, Bruce Camitta
No abstract text is available yet for this article.
July 19, 2024: Journal of Pediatric Hematology/oncology
Mayumi Kamata, Atsushi Fusegi, Nozomi Kurihara, Akiko Abe, Hidetaka Nomura, Hiroyuki Kanao
OBJECTIVE: Minimally invasive radical hysterectomy has a worse prognosis than open surgery, but the reasons for the poor prognosis remain unclear. Tumor spillage occurs when the tumor is exposed to the surgical field and has been suggested to be related to a poor prognosis. This study aimed to compare the prognostic value of tumor spillage in laparoscopic radical hysterectomy and evaluate whether tumor spillage prevention improves oncological safety. METHODS: We compared the prognosis of patients who underwent laparoscopic radical hysterectomy between December 2014 and November 2021 with or without tumor spillage prevention, including surgeries without prevention and those with failed prevention...
July 12, 2024: Journal of Gynecologic Oncology
Bo Ra Kim, Hyejin Ko, Dahye Son, Ji Eun Shim, Yun Hwan Kim
OBJECTIVE: We investigated the effect of our quality control (QC) program on the management strategy, completeness of the surgery, and clinical outcomes in advanced ovarian cancer. METHODS: A retrospective review of medical records from January 2005 to December 2019 identified 129 patients with advanced ovarian cancer. Cases were categorized into group 1 (2005-2013) and group 2 (2014-2019) before and after implementation of the QC program. Comparisons included clinicopathological variables, operative details, recurrence and survival outcomes...
July 5, 2024: Journal of Gynecologic Oncology
Takashi Motohashi, Muneaki Shimada, Hideki Tokunaga, Yuki Kuwahara, Hiroyo Kuwabara, Ai Kato, Tsutomu Tabata
OBJECTIVE: Epithelial ovarian cancer (EOC) is the leading cause of female mortality in gynecologic malignancies, with a rising incidence in Japan. This study aimed to validate the treatment patterns and safety of niraparib as maintenance therapy for EOC following initial chemotherapy in clinical practice in Japan. METHODS: Leveraging claims data between April 2008 and December 2022, this descriptive study comprised EOC-diagnosed patients receiving initial platinum-based chemotherapy, debulking surgery, and niraparib as maintenance therapy...
July 4, 2024: Journal of Gynecologic Oncology
Chel-Hun Choi, Yoo-Young Lee, Yen-Ling Lai, Koping Chang, Hyun-Soo Kim, Jung Chen, Yu-Li Chen
OBJECTIVE: In this study, we evaluated the role of prolonged progestin treatment on atypical endometrial hyperplasia (AEH) patients who did not achieve complete regression (CR) after at least 3 months of progestin treatment. Possible prognostic factors predicting disease regression and recurrence were also assessed. METHODS: We retrospectively identified patients who had histologically confirmed persistent disease after at least 3 months of progestin treatment at two tertiary centers in Korea and Taiwan...
July 8, 2024: Journal of Gynecologic Oncology
Yeon Jee Lee, Ji Hyun Kim, Youn Jee Kim, Yoon Jung Chang, Sun-Young Kong, Chong Woo Yoo, Dong Ock Lee, Sang-Soo Seo, Sokbom Kang, Sang-Yoon Park, Myong Cheol Lim
OBJECTIVE: To investigate the prevalence of pathological findings and clinical outcomes of risk-reducing salpingo-oophorectomy (RRSO) in asymptomatic carriers with germline homologous recombination repair (HRR) gene pathogenic/likely pathogenic variants (PV/LPV). METHODS: This retrospective study enrolled asymptomatic carriers with germline HR gene PV/LPV who underwent RRSO between 2006 and 2022 at the National Cancer Center in Korea. Clinical characteristics, including history of breast cancer, family history of ovarian/breast cancer, parity, and oral contraceptive use, were analyzed...
July 5, 2024: Journal of Gynecologic Oncology
Kai Zhang, Jeremy Teoh, Gang Zhu, Chi-Fai Ng, Michel Suberville, Pilar Laguna, Jean de la Rosette
PURPOSE: Irreversible electroporation (IRE) is a promising alternative treatment for low-intermediate-risk localized prostate cancer. In this systematic review we aim to evaluate the safety profile and functional and oncological outcomes of this new technique. MATERIALS AND METHODS: A systematic review of the literature was performed on PubMed, EMBASE, and Scopus up to 24 August 2023. Nineteen studies were analyzed, including 12 prospective studies and 7 retrospective studies...
July 3, 2024: World Journal of Men's Health
Maciej Borys, Michał Wysocki, Krystyna Gałązka, Andrzej Budzyński
BACKGROUND: Spleen preservation during laparoscopic distal pancreatectomy (LSPDP) should be pursued if safe and oncologically justified. The aim of the presented study was to compare surgical outcomes and identify risk factors for unplanned splenectomy during laparoscopic distal pancreatectomy and evaluate short and long-terms outcomes. METHODS: The following study is a retrospective cohort study of consecutive patients who underwent laparoscopic distal pancreatectomy, with the intention of preserving the spleen, for benign tumors of the body and tail of the pancreas between August 2012 and December 2022...
July 19, 2024: Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
Fuhai Wang, Xiaofeng Dong, Peng Xiu, Jingtao Zhong, Honglong Wei, Zongzhen Xu, Tao Li, Feng Liu, Xueying Sun, Jie Li
Following the publication of this article, an interested reader drew to the authors' attention that two pairs of protein bands featured in the western blots in Fig. 3A and 5D on p. 679 and 681 respectively appeared to be strikingly similar. After having re‑examined their original data, the authors realized that Fig. 5D had been assembled incorrectly. The revised version of Fig. 5, now including the correct data for Fig. 5D, is shown on the next page. Note that the errors made in terms of assembling the data in Fig...
September 2024: Oncology Reports
Jing Zhang, Linghua Wu, Rong Ding, Xin Deng, Zeshan Chen
MicroRNAs (miRNAs) are small non‑coding RNAs that serve key roles in cell proliferation, migration, invasion and apoptosis by regulating gene expression. In malignant tumors, miRNA‑122 serves either as a tumor suppressor or oncogene, influencing tumor progression via downstream gene targeting. However, the precise role of miRNA‑122 in cancer remains unclear. miRNA‑122 is a potential biomarker and modulator of radiotherapy and chemotherapy. The present review aimed to summarize the roles of miRNA‑122 in cancer, its potential as a biomarker for diagnosis and prognosis and its implications in cancer therapy, including radiotherapy and chemotherapy, alongside strategies for systemic delivery...
September 2024: International Journal of Oncology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.